Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition

Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities.

Bora Pharmaceuticals is CGMP CDMO with specialties in complex oral solid dosage, non-sterile liquids, nasal sprays, and semi-solid pharmaceutical products. With three manufacturing facilities in Taiwan and Canada, Bora services 100 markets around the world. TWi Pharmaceuticals is a leading pharmaceutical company based in Taipei, Taiwan, with a focus on generic prescription drugs with a high barrier-to-entry. These range from oral controlled release dosage forms, as well as novel drug delivery systems such as nanoparticles, transdermal, and polymeric oral delivery systems.  

With TWi’s track record of strong formulation development, Bora hopes to add and expand their capabilities as a full service CDMO. While TWi Pharmaceuticals USA operations will remain a separate entity while benefitting from Bora’s existing production capacity, transferring some commercial manufacturing of generic and 505b2 drugs in the United States to Bora. 

CEO of Bora Pharmaceuticals Bobby Sheng commented on the acquisition: “The acquisition of TWi Pharmaceuticals marks a huge milestone in Bora’s history as we become the largest pharmaceutical group by volume in Taiwan. TWi has a long history of strong formulation development, as well as an impeccable quality track record. As a result of acquiring TWi, Bora will be able to further expand on our capabilities as a full service CDMO. I’m looking forward to continuing our growth in this industry.”